Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Trials. 2012 Nov 21;13:219. doi: 10.1186/1745-6215-13-219.
To improve risk factor management in diabetes, we need to support effective interactions between patients and healthcare providers. Our aim is to develop and evaluate a treatment decision aid that offers personalised information on treatment options and outcomes, and is intended to empower patients in taking a proactive role in their disease management. Important features are: (1) involving patients in setting goals together with their provider; (2) encourage them to prioritise on treatments that maximise relevant outcomes; and (3) integration of the decision aid in the practice setting and workflow. As secondary aim, we want to evaluate the impact of different presentation formats, and learn more from the experiences of the healthcare providers and patients with the decision aid.
We will conduct a randomised trial comparing four formats of the decision aid in a 2 × 2 factorial design with a control group. Patients with type 2 diabetes managed in 18 to 20 primary care practices in The Netherlands will be recruited. Excluded are patients with a recent myocardial infarction, stroke, heart failure, angina pectoris, terminal illness, cognitive deficits, > 65 years at diagnosis, or not able to read Dutch. The decision aid is offered to the patients immediately before their quarterly practice consultation. The same decision information will be available to the healthcare provider for use during consultation. In addition, the providers receive a set of treatment cards, which they can use to discuss the benefits and risks of different options. Patients in the control group will receive care as usual. We will measure the effect of the intervention on patient empowerment, satisfaction with care, beliefs about medication, negative emotions, health status, prescribed medication, and predicted cardiovascular risk. Data will be collected with questionnaires and automated extraction from medical records in 6 months before and after the intervention.
This decision aid is innovative in supporting patients and their healthcare providers to make shared decisions about multiple treatments, using the patient's data from electronic medical records. The results can contribute to the further development and implementation of electronic decision support tools for the management of chronic diseases.
Dutch Trial register NTR1942.
为了改善糖尿病的危险因素管理,我们需要支持患者和医疗保健提供者之间的有效互动。我们的目标是开发和评估一种治疗决策辅助工具,提供有关治疗选择和结果的个性化信息,并旨在使患者在疾病管理中发挥积极主动的作用。重要特征包括:(1)让患者与他们的提供者一起设定目标;(2)鼓励他们优先考虑能最大限度提高相关结果的治疗方法;(3)将决策辅助工具整合到实践环境和工作流程中。作为次要目标,我们希望评估不同呈现格式的影响,并从医疗保健提供者和患者对决策辅助工具的经验中学习更多。
我们将进行一项随机试验,在 2×2 析因设计中比较决策辅助工具的四种格式,并设有对照组。将招募荷兰 18 至 20 个初级保健实践中的 2 型糖尿病患者。排除标准包括近期心肌梗死、中风、心力衰竭、心绞痛、终末期疾病、认知障碍、诊断时>65 岁或不能阅读荷兰语的患者。决策辅助工具将在患者每季度就诊前立即提供给他们。相同的决策信息将提供给医疗保健提供者,以便在就诊期间使用。此外,提供者将收到一套治疗卡,用于讨论不同选择的益处和风险。对照组的患者将接受常规护理。我们将测量干预对患者授权、护理满意度、对药物的信念、负面情绪、健康状况、处方药物和预测心血管风险的影响。在干预前后的 6 个月内,将通过问卷和从医疗记录中自动提取数据来收集数据。
该决策辅助工具在支持患者及其医疗保健提供者就多种治疗方法做出共同决策方面具有创新性,使用来自电子病历的患者数据。研究结果可以为进一步开发和实施用于管理慢性病的电子决策支持工具做出贡献。
荷兰试验注册 NTR1942。